Ovarian Cancer

Shana Wingo, M.D., discusses surgery's changing role in the treatment of ovarian cancer.

PARP inhibitors like Rubraca and Lynparza continue to shape the treatment landscape of ovarian cancer.

The FDA has approved Zejula (niraparib) for treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in the maintence setting.

Results from a randomized trial suggest maintenance chemotherapy after debulking surgery and adjuvant platinum-based chemotherapy do not improve overall survival rates among women with ovarian cancer who had achieved remission.

Hormonal maintenance therapy may be able to improve PFS rates for some patients with ovarian cancer, according to a recent study.

Patients with BRCA-mutant ovarian cancer saw an improved progression-free survival with Lynparza, according to a recent study.

Improved overall survival (OS) was achieved in patients with BRCA-proficient ovarian cancer who were treated with a carboplatin desensitization regimen.

Jubilee Brown, M.D., obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.

PARP inhibitors like niraparib are bringing big change to the treatment of ovarian cancer, says Kathleen N. Moore, M.D.

Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.

The PARP inhibitor niraparib proved to be effective in improving progression-free survival in recurrent ovarian cancer, according to a recent study.

Concern about vaccine safety and perceived lack of necessity remain the main reasons parents give for not having their teenage daughter vaccinated against HPV.

Jubilee Brown, M.D., answers some common questions about genetic counseling in patients with ovarian cancer.

Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.

Elizabeth Swisher, M.D., discusses the ARIEL2 study, which proved that rucaparib may be a promising agent for patients with recurrent ovarian cancer.

Elizabeth Swisher, M.D., professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the side effects of rucaparib in the ARIEL2 trial, for patients with relapsed, platinum-sensitive high-grade ovarian carcinoma.

Marcia Goglia was given a laxative in the ER for what turned out to be ovarian cancer.

Diagnostic laparoscopy can play a role in predicting surgery outcomes for patients with ovarian cancer.

The best chemotherapy strategy (IP versus IV) for patients with ovarian cancer is still being debated. Franco M. Muggia, M.D., weighs in.

The Georgia Ovarian Cancer Alliance compiled a book of stories from women who were touched by ovarian cancer.

An expanded access program (EAP) was just opened up for ceratain patients with ovarian cancer to receive niraparib.

A recent study examined the relationship between polycystic ovarian syndrome, long or irregular periods and ovarian cancer risk.

Finding new biomarkers should be the top priority in ovarian cancer research, Maurie Markman, M.D., says.

The FDA approved Rubraca for patients with advanced ovarian cancer who already had two or more lines of therapy.